Abstract：Objective： To evaluate the efficacy and toxicity of abiraterone combined with goserelin for the treatment of metastatic castration-resistant prostate cancer （mCRPC） after radical prostatectomy. Methods： Two patients who received the radical resection of the prostate with mCRPC in our hospital from January 2019 to December 2021 were enrolled into the study. Postoperative pathological examination revealed the positive cut edge. The median postoperative progression to mCRPC was 18.5 months. These patients received abiraterone （1,000 mg once daily）, plus prednisone（5 mg twice daily） and goserelin （10.8mg trimonthly）.The PSA response rate and side effects of the drugs were recorded. Results： The median follow-up duration was 22 months. The two patients had a PSA overall relief. There was one case of the PSA Flare phenomenon. There was no adverse effect leading to discontinuation of drug therapy. Conclusion： In the treatment of mCRPC,combination of abiraterone and goserelin is aneffective and safe option.
孙允冀, 张恒, 孙晓璐. 阿比特龙联合戈舍瑞林治疗前列腺根治性切除术后转移性去势抵抗前列腺癌患者的临床效果[J]. 微创泌尿外科杂志, 2022, 11(2): 91-94.
Sun Yunji, Zhang Heng, Sun Xiaolu. Abiraterone combined with goserelin for the treatment of metastatic castration-resistant prostate cancer after radical prostatectomy. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2022, 11(2): 91-94.
[1] CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[2] HELLERSTEDT B, PIENTA KJ.The current state of hormonal therapy for prostate cancer[J]. CA Cancer J Clin,2002,52(3):154-179.
[3] BODY J J, CASIMIRO S, COSTA L.Targeting bone metastases in prostate cancer: improving clinical outcome[J]. Nat Rev Urol,2015,12(6):340-356.
[4] 陈鸿杰. 醋酸阿比特龙治疗去势抵抗性前列腺癌的研究进展[J].国际泌尿系统杂志,2015,35(3):437-439.
[5] 中国抗癌协会泌尿肿瘤专业委员会.中国去势抵抗性前列腺癌诊治专家共识[J].中华外科杂志,2016,54(7):481-484.
[6] 刘浩,彭倩,何阳科,等.阿比特龙联合强的松治疗去势抵抗性前列腺癌的临床观察[J].实用医院临床杂志,2018,15(4):49-51.
[7] 中国抗癌协会泌尿男生殖系肿瘤专业委员会.2018版转移性前列腺癌诊治中国专家共识[J].中华外科杂志,2018,56(9):646-652.
[8] ATTARD G, BELLDEGRUN AS, DE BONO J S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer[J]. BJU Int,2005,96(9):1241-1246.
[9] SYDES MR, SPEARS MR, MASON MD, et al.Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol[J]. Ann Oncol,2018,29(5):1235-1248.
[10] FIZAZI K, SCHER HI, MOLINA A, et al.Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol,2012,13(10):983-992.
[11] RYAN C J, SMITH M R, FIZAZI K, et al.Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302):final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol,2015,16(2):152-160.
[12] BOLLA M, VAN POPPEL H, COLLETTE L, et al.Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)[J]. Lancet,2005,366(9485):572-578.
[13] THOMPSON I M, VALICENTI R K, ALBERTSEN P.Adjuvant and salvage radiotherapy after prostatectomy:AUA/ASTRO guidelines[J]. J Urol,2013,86: 822-828.
[14] SCHER HI, MORRIS MJ, STADLER WM, et al.Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3[J]. J Clin Oncol,2016;34(12):1402-1418.
[15] 单兴利, 王栋, 胡林军,等. 阿比特龙治疗转移性去势抵抗性前列腺癌的PSA闪烁现象观察[J]. 现代泌尿生殖肿瘤杂志,2020,12(3):162-167
